Biologics, theranostics, and personalized medicine in drug delivery systems
The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge te...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Matteo Puccetti [verfasserIn] Marilena Pariano [verfasserIn] Aurélie Schoubben [verfasserIn] Stefano Giovagnoli [verfasserIn] Maurizio Ricci [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2024 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Pharmacological Research ; 201(2024), Seite 107086- volume:201 ; year:2024 ; pages:107086- |
|---|
| Links: |
|---|
| DOI / URN: |
10.1016/j.phrs.2024.107086 |
|---|
| Katalog-ID: |
DOAJ09590865X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09590865X | ||
| 003 | DE-627 | ||
| 005 | 20240414201420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2024.107086 |2 doi | |
| 035 | |a (DE-627)DOAJ09590865X | ||
| 035 | |a (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Matteo Puccetti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biologics, theranostics, and personalized medicine in drug delivery systems |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. | ||
| 650 | 4 | |a Biologics | |
| 650 | 4 | |a Innovative delivery systems | |
| 650 | 4 | |a Theranostics | |
| 650 | 4 | |a Nanomedicine | |
| 650 | 4 | |a Personalized medicine | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Marilena Pariano |e verfasserin |4 aut | |
| 700 | 0 | |a Aurélie Schoubben |e verfasserin |4 aut | |
| 700 | 0 | |a Stefano Giovagnoli |e verfasserin |4 aut | |
| 700 | 0 | |a Maurizio Ricci |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmacological Research |g 201(2024), Seite 107086- |
| 773 | 1 | 8 | |g volume:201 |g year:2024 |g pages:107086- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.phrs.2024.107086 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1043661824000306 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1096-1186 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2024 |h 107086- | ||
| author_variant |
m p mp m p mp a s as s g sg m r mr |
|---|---|
| matchkey_str |
matteopuccettimarilenaparianoaurlieschou:2024----:ilgcteaotcadesnlzdeiienr |
| hierarchy_sort_str |
2024 |
| callnumber-subject-code |
RM |
| publishDate |
2024 |
| allfields |
10.1016/j.phrs.2024.107086 doi (DE-627)DOAJ09590865X (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 DE-627 ger DE-627 rakwb eng RM1-950 Matteo Puccetti verfasserin aut Biologics, theranostics, and personalized medicine in drug delivery systems 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine Therapeutics. Pharmacology Marilena Pariano verfasserin aut Aurélie Schoubben verfasserin aut Stefano Giovagnoli verfasserin aut Maurizio Ricci verfasserin aut In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- https://doi.org/10.1016/j.phrs.2024.107086 kostenfrei https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661824000306 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 201 2024 107086- |
| spelling |
10.1016/j.phrs.2024.107086 doi (DE-627)DOAJ09590865X (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 DE-627 ger DE-627 rakwb eng RM1-950 Matteo Puccetti verfasserin aut Biologics, theranostics, and personalized medicine in drug delivery systems 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine Therapeutics. Pharmacology Marilena Pariano verfasserin aut Aurélie Schoubben verfasserin aut Stefano Giovagnoli verfasserin aut Maurizio Ricci verfasserin aut In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- https://doi.org/10.1016/j.phrs.2024.107086 kostenfrei https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661824000306 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 201 2024 107086- |
| allfields_unstemmed |
10.1016/j.phrs.2024.107086 doi (DE-627)DOAJ09590865X (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 DE-627 ger DE-627 rakwb eng RM1-950 Matteo Puccetti verfasserin aut Biologics, theranostics, and personalized medicine in drug delivery systems 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine Therapeutics. Pharmacology Marilena Pariano verfasserin aut Aurélie Schoubben verfasserin aut Stefano Giovagnoli verfasserin aut Maurizio Ricci verfasserin aut In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- https://doi.org/10.1016/j.phrs.2024.107086 kostenfrei https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661824000306 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 201 2024 107086- |
| allfieldsGer |
10.1016/j.phrs.2024.107086 doi (DE-627)DOAJ09590865X (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 DE-627 ger DE-627 rakwb eng RM1-950 Matteo Puccetti verfasserin aut Biologics, theranostics, and personalized medicine in drug delivery systems 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine Therapeutics. Pharmacology Marilena Pariano verfasserin aut Aurélie Schoubben verfasserin aut Stefano Giovagnoli verfasserin aut Maurizio Ricci verfasserin aut In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- https://doi.org/10.1016/j.phrs.2024.107086 kostenfrei https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661824000306 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 201 2024 107086- |
| allfieldsSound |
10.1016/j.phrs.2024.107086 doi (DE-627)DOAJ09590865X (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 DE-627 ger DE-627 rakwb eng RM1-950 Matteo Puccetti verfasserin aut Biologics, theranostics, and personalized medicine in drug delivery systems 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine Therapeutics. Pharmacology Marilena Pariano verfasserin aut Aurélie Schoubben verfasserin aut Stefano Giovagnoli verfasserin aut Maurizio Ricci verfasserin aut In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- https://doi.org/10.1016/j.phrs.2024.107086 kostenfrei https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661824000306 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 201 2024 107086- |
| language |
English |
| source |
In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- |
| sourceStr |
In Pharmacological Research 201(2024), Seite 107086- volume:201 year:2024 pages:107086- |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Pharmacological Research |
| authorswithroles_txt_mv |
Matteo Puccetti @@aut@@ Marilena Pariano @@aut@@ Aurélie Schoubben @@aut@@ Stefano Giovagnoli @@aut@@ Maurizio Ricci @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| id |
DOAJ09590865X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ09590865X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414201420.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2024.107086</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09590865X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Matteo Puccetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biologics, theranostics, and personalized medicine in drug delivery systems</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Innovative delivery systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Theranostics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanomedicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marilena Pariano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aurélie Schoubben</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Giovagnoli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Ricci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmacological Research</subfield><subfield code="g">201(2024), Seite 107086-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:201</subfield><subfield code="g">year:2024</subfield><subfield code="g">pages:107086-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2024.107086</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1043661824000306</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1096-1186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">201</subfield><subfield code="j">2024</subfield><subfield code="h">107086-</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Matteo Puccetti |
| spellingShingle |
Matteo Puccetti misc RM1-950 misc Biologics misc Innovative delivery systems misc Theranostics misc Nanomedicine misc Personalized medicine misc Therapeutics. Pharmacology Biologics, theranostics, and personalized medicine in drug delivery systems |
| authorStr |
Matteo Puccetti |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| topic_title |
RM1-950 Biologics, theranostics, and personalized medicine in drug delivery systems Biologics Innovative delivery systems Theranostics Nanomedicine Personalized medicine |
| topic |
misc RM1-950 misc Biologics misc Innovative delivery systems misc Theranostics misc Nanomedicine misc Personalized medicine misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc Biologics misc Innovative delivery systems misc Theranostics misc Nanomedicine misc Personalized medicine misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc Biologics misc Innovative delivery systems misc Theranostics misc Nanomedicine misc Personalized medicine misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Pharmacological Research |
| hierarchy_top_title |
Pharmacological Research |
| isfreeaccess_txt |
true |
| title |
Biologics, theranostics, and personalized medicine in drug delivery systems |
| ctrlnum |
(DE-627)DOAJ09590865X (DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93 |
| title_full |
Biologics, theranostics, and personalized medicine in drug delivery systems |
| author_sort |
Matteo Puccetti |
| journal |
Pharmacological Research |
| journalStr |
Pharmacological Research |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2024 |
| contenttype_str_mv |
txt |
| container_start_page |
107086 |
| author_browse |
Matteo Puccetti Marilena Pariano Aurélie Schoubben Stefano Giovagnoli Maurizio Ricci |
| container_volume |
201 |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Matteo Puccetti |
| doi_str_mv |
10.1016/j.phrs.2024.107086 |
| author2-role |
verfasserin |
| title_sort |
biologics, theranostics, and personalized medicine in drug delivery systems |
| callnumber |
RM1-950 |
| title_auth |
Biologics, theranostics, and personalized medicine in drug delivery systems |
| abstract |
The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. |
| abstractGer |
The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. |
| abstract_unstemmed |
The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Biologics, theranostics, and personalized medicine in drug delivery systems |
| url |
https://doi.org/10.1016/j.phrs.2024.107086 https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93 http://www.sciencedirect.com/science/article/pii/S1043661824000306 https://doaj.org/toc/1096-1186 |
| remote_bool |
true |
| author2 |
Marilena Pariano Aurélie Schoubben Stefano Giovagnoli Maurizio Ricci |
| author2Str |
Marilena Pariano Aurélie Schoubben Stefano Giovagnoli Maurizio Ricci |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.phrs.2024.107086 |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T17:19:41.237Z |
| _version_ |
1803579221599059968 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ09590865X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414201420.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2024.107086</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09590865X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3c34222cbbbd4b6480dad03a49327f93</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Matteo Puccetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biologics, theranostics, and personalized medicine in drug delivery systems</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Innovative delivery systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Theranostics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanomedicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marilena Pariano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aurélie Schoubben</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Giovagnoli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Ricci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmacological Research</subfield><subfield code="g">201(2024), Seite 107086-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:201</subfield><subfield code="g">year:2024</subfield><subfield code="g">pages:107086-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2024.107086</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3c34222cbbbd4b6480dad03a49327f93</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1043661824000306</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1096-1186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">201</subfield><subfield code="j">2024</subfield><subfield code="h">107086-</subfield></datafield></record></collection>
|
| score |
7.401516 |